CCM
ITCI

Cupps Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Cupps Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-51,995
Closed -$2.02M – 198
2016
Q2 		$2.02M Buy
51,995
+62
+0.1% +$2.23K 0.52% 74
2016
Q1 		$1.44M Sell
51,933
-27,391
-35% -$913K 0.28% 107
2015
Q4 		$4.27M Buy
+79,324
New +$4M 0.6% 65

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Cupps Capital Management's ITCI Position: Q3 2016 in Review

Cupps Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2016, closing a stake of 51,995 shares — an estimated $2.02M sold.

Cupps Capital Management first reported a position in ITCI in Q4 2015 and held it in 3 quarters. The position peaked at $4.27M in Q4 2015. 132 funds tracked by Wall St. Rank hold ITCI as of Q3 2016.

  • Cupps Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2016 after selling out during the quarter.
  • Cupps Capital Management sold 51,995 Intra-Cellular Therapies Inc. shares in Q3 2016, an estimated $2.02M.
  • Cupps Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2015 and held it in 3 quarters.
  • Cupps Capital Management's Intra-Cellular Therapies Inc. position peaked at $4.27M in Q4 2015.
  • 132 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2016.

Based on Cupps Capital Management's 13F filing for Q3 2016, filed 11 Oct 2016.